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Abstract
Aims Morphine is shown to relieve chronic breathlessness in chronic obstructive pulmonary disease. There are no deﬁnitive
data in people with heart failure. We aimed to determine the effectiveness and cost-effectiveness of 12 weeks morphine ther-
apy for the relief of chronic breathlessness in people with chronic heart failure compared with placebo.
Methods and results Parallel group, double-blind, randomized, placebo-controlled, phase III trial of 20mg daily oral modiﬁed
release morphine was conducted in 13 sites in England and Scotland: hospital/community cardiology or palliative care outpa-
tients. The primary analysis compared between-group numerical rating scale average breathlessness/24 hours at week 4 using
a covariance pattern linear mixed model. Secondary outcomes included treatment-emergent harms (worse or new). The trial
closed early due to slow recruitment, randomizing 45 participants [average age 72 (range 39–89) years; 84%men; 98%New York
Heart Association class III]. For the primary analysis, the adjusted mean difference was 0.26 (95% conﬁdence interval, 0.86 to
1.37) in favour of placebo. All other breathlessness measures improved in both groups (week 4 change-from-baseline) but by
more in those assigned to morphine. Neither group was excessively drowsy at baseline or week 4. There were no between-
group differences in quality of life (Kansas) or cognition (Montreal) at any time point. There was no exercise-related desaturation
and no change between baseline andweek 4 in either group. There was no change in vital signs at week 4. The natriuretic peptide
measures fell in both groups but by more in the morphine group [morphine 2169 (1092, 3851) pg/mL vs. placebo 2851 (1694,
5437)] pg/mL. There was no excess serious adverse events in the morphine group. Treatment-emergent harms during the ﬁrst
week were more common in the morphine group; all apart from 1 were ≤ grade 2.
Conclusions We could not answer our primary objectives due to inadequate power. However, we provide novel placebo-
controlled medium-term beneﬁt and safety data useful for clinical practice and future trial design. Morphine should only be
prescribed in this population when other measures are unhelpful and with early management of side effects.
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Introduction
Although modern medical therapy is successful in improving
morbidity and mortality in patients with chronic heart failure,
for some, breathlessness persists1 despite optimal pharmaco-
logical therapy. Persisting breathlessness is associated with
poorer physical and mental quality of life,2 impaired activities
of daily living,3 increased unplanned hospital attendance4
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and admissions,5 and higher mortality.3 Although non-
pharmacological and pharmacological interventions can re-
duce its impact, its importance to patients is often neglected
in guidelines and clinical trials.6–8
The perception of breathlessness is processed in brain
areas9 rich in opioid receptors.10 Endogenous opioids reduce
breathlessness, whereas the opioid antagonist, naloxone, in-
creases exertion-induced breathlessness by blocking the ef-
fects of endogenous opioids on the brain.11,12 In people
with chronic breathlessness due to a range of causes, but
mainly chronic obstructive pulmonary disease, regular, low
dose, modiﬁed release morphine is safe and effective in the
short term (7 days).7,13 However, the evidence is less clear
in people with chronic heart failure.14,15 Preliminary data sug-
gest that people with chronic heart failure may beneﬁt from
morphine given for 3 months.16 Despite the lack of deﬁnitive
data, morphine is used in clinical practice although there is
wide variation in willingness to prescribe, dosing, and quality
of monitoring. Potential problems are (i) patients may be de-
nied a helpful medication (due to unfounded fears about
harms17 and addiction);18 (ii) they may have a poorly moni-
tored, suboptimal regime; and (iii) there may be no net ben-
eﬁt in the longer term (although there is no evidence of
tachyphylaxis to date).
We therefore designed BreatheMOR-HF to determine
whether morphine therapy given for up to 12 weeks is supe-
rior to placebo for the relief of chronic breathlessness in am-
bulatory patients with chronic heart failure who remained
symptomatic despite guideline-recommended medical ther-
apy. The trial closed early due to poor recruitment but col-
lected important medium-term placebo-controlled data
especially on toxicity and safety, which we report here.
Methods
Trial design
BreatheMOR-HF was a 12 week, parallel group, double-blind,
randomized, placebo-controlled, ﬁxed dosed, multi-site,
phase III trial of 20 mg daily oral modiﬁed release morphine
measuring breathlessness intensity in ambulatory patients
with symptomatic chronic heart failure.
Participants and setting
Patients from 13 centres in England and Scotland, attending
hospital/community cardiology or palliative care clinics or
hospices, were screened by research nurses in conjunction
with the patients’ usual clinical team. Eligible participants (i)
were aged ≥18 years; (ii) had New York Heart Association
(NYHA) class III/IV symptoms; (iii) had either left ventricular
systolic dysfunction deﬁned as left ventricular ejection
fraction <40% or left ventricular ejection fraction >40%
and left ventricular hypertrophy, left atrial dilation or abnor-
mal diastolic function; (iv) had N-terminal-pro-B-type natri-
uretic peptide ≥1000 pg/mL or B-type natriuretic peptide
≥250 pg/mL within the last 3 months; (v) were on a
guideline-recommended medical treatment for chronic heart
failure and unchanged for ≥2 weeks; (vi) had a glomerular ﬁl-
tration rate ≥30 mL/min(/1.73m2) within 2 weeks; and (vii)
scored ≥grade 2 on the modiﬁed Medical Research Council
(mMRC) breathlessness scale.
Optimal medical management for people with reduced left
ventricular function was deﬁned as a maximally tolerated
dose of an inhibitor of the renin-angiotensin system and a
beta-adrenoceptor antagonist and a mineralocorticoid recep-
tor antagonist. People with preserved left ventricular func-
tion were required only to receive diuretics and treatment
for ventricular rate control for atrial ﬁbrillation. Patients un-
able to provide written informed consent or complete study
questionnaires, had co-existing relevant neoplasia, had used
opioids regularly within the last month at a daily dose ≥ study
dose, or had a documented contra-indication to morphine
were excluded.
Randomization
Random allocations (1:1; stratiﬁed block randomization by
centre; randomly permuted block sizes of 2 and 4; investiga-
tors blinded to block size) were centrally generated by an on-
line secure service (sealed envelope™) following eligibility
data entry of consented participants by a site researcher.
Approvals
The protocol, amendments, and trial documentation were
approved by the North West-Liverpool Central Research
Ethics Committee (ref. 14/NW/0277; 7 January 2014). Medi-
cines and Healthcare products Regulatory Agency approval
was received (9 November 2014). NHS site approvals were
obtained, and the trial was registered (ISRCTN41349358)
prior to recruitment.
Intervention and comparator
Participants were allocated to capsules of 10 mg modiﬁed re-
lease morphine [MST® CONTINUS® (https://www.medicines.
org.uk/emc/product/7666/smpc)] or placebo that were iden-
tical in appearance, taste, and smell. Capsules were to be
taken orally twice daily.
Blinding
Participants, research team members, and clinicians were
blind to treatment allocation. Site pharmacists received the
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capsules unblinded with a tear-off strip to allow blinding at
the time of dispensing. To prevent unblinding due to consti-
pation, a laxative (100 mg docusate) capsule was given twice
daily to patients assigned to morphine and an identical pla-
cebo to those assigned to the placebo-control group.
Procedures
Participants’ demographic and clinical details were recorded
at baseline prior to randomization. Serum urea, electrolytes,
and creatinine were measured within 2 weeks of randomiza-
tion. Renal clearance was assessed using estimated glomeru-
lar ﬁltration rate or calculated using the Cockroft and Gault
method.19 The Charlson Comorbidity Score20 and modiﬁed
Medical Research Council breathlessness scale21 were also re-
corded at baseline.
Outcome data were collected at days 2, 4, and 7 and
weeks 2, 3, 4, 8, and 12 after randomization during home
or clinic visits or by telephone (depending upon the outcomes
and patient preference).
The primary endpoint was measured at week 4. Capsules
were dispensed at baseline and at 4 and 8 weeks. Each time,
56 morphine/placebo and 56 placebo/docusate capsules
were dispensed. Participants were advised not to drive during
the ﬁrst week and asked to return unused capsules for com-
pliance reconciliation.
At the end of 12 weeks, participants could choose whether
to take open-label morphine following the same regimen as
the trial but prescribed and monitored by their usual-care
clinician. The trial was closed early, due to slow recruitment,
in May 2018; the last participant completed follow-up in
August 2018.
Outcomes
The primary outcome measure was the average numerical
rating scale breathlessness intensity score over the previous
24 h22 assessed at 4 weeks. Table 1 details primary and
secondary outcomes.
Sample size
Based on our previous data,15 a 1 point difference on the
breathlessness scale was chosen to demonstrate a minimum
clinically important difference. In order to detect this differ-
ence between the groups at 4 weeks with 90% power at 5%
signiﬁcance (and assuming a standard deviation of 2.55, giv-
ing a medium effect size of 0.4), 138 patients were required
in each group. Allowing for 20% attrition, we needed 346 pa-
tients (173 to each group).
Statistical analysis
Analyses were conducted in Stata v13 (StataCorp. 2013. Stata
Statistical Software: Release 13. College Station, TX:
StataCorp LP) on an intention-to-treat basis. Statistical tests
were two-sided at 5% signiﬁcance level. Baseline data are
summarized overall and by trial arm both by randomization
and separately for participants providing data to the primary
endpoint. No statistical comparisons between treatment
groups were undertaken on baseline data.
The primary analysis compared the NRS average breath-
lessness at week 4 between the morphine and placebo
groups using a covariance pattern linear mixed model. The
outcomes were numerical rating scale at each post-
randomization time point (≤week 12), nested within patients.
Scores at baseline, trial arm, time point, and a time-by-trial
arm interaction were included as ﬁxed-effects with partici-
pant and site as random-effects. An independent covariance
structure for the repeated measurements was used as this
provided the smallest Akaike’s information criterion.35
The adjusted mean difference, with its associated 95% con-
ﬁdence interval and P value, between the two groups for the
week 4 time point was extracted from the model.
The secondary outcomes of the Australian-modiﬁed
Karnofsky Performance Scale, Kansas City Cardiomyopathy
Questionnaire-12, and Karolinska Sleepiness Scale were simi-
larly analysed. The Epworth Sleep Scale, Montreal Cognitive
Assessment, 6 min walk test, and activPAL™ were analysed
using mixed-effect linear regression to compare the scores
at week 4 adjusting for baseline score and site as a random
effect (i.e. repeated measures per participant not required
to be included).
Data on study drug use are described in Supporting Infor-
mation, Table S5, with adverse event data presented by trial
arm in Supporting Information, Tables S4A and S4B and on
harms in Supporting Information, Tables S5A and S5B.
A full cost-effectiveness analysis was originally planned;
however, as the study is underpowered, EQ-5D-5L and health
resource use data are summarized descriptively (Supporting
Information, Tables S4A and S4B).
This study report uses the CONSORT framework for
reporting randomized clinical trials.36
Results
Thirteen sites opened to recruitment and seven randomized
at least one participant. The ﬁrst participant was randomized
in June 2016 and recruitment closed in May 2017; by which
time, 45 patients had been recruited and randomized (21 to
morphine and 24 to placebo).
Altogether, 386 patients were screened between Decem-
ber 2015 and May 2017 (median 27 per site, range 0–55),
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Table 1 Overview of primary and secondary outcomes
Primary outcome Average breathlessness over the previous 24 h [baseline, D2, D4, D7, W2, W3, W4 (primary time point), W8,
and W12]
○ 0–10 (11 points) NRS22
○ 0 = none to 10 = worst imaginable
Other breathlessness
assessments
Intensity of worst breathlessness over the previous 24 h; distress due to breathlessness over the previous 24 h;
unpleasantness of breathlessness over the previous 24 h (baseline, D2, D4, D7, W2, W3, W4, W8, and W12)
○ 0–10 (11 points) NRS22
○ 0 = none to 10 = worst imaginable
Global impression of change (W4)23
○ Subjective measure of response to treatment
○ Participants asked if their breathlessness has changed and by how much using a verbal rating scale
Related symptoms Average pain over previous 24 h (baseline, D2, D4, D7, W2, W3, W4, W8, and W12)
○ 0–10 (11 point) NRS24
○ 0 = no pain to 10 = worst imaginable pain
Epworth Sleepiness Scale (ESS; baseline and W4)25
○ Screening tool for sleep-disordered breathing
○ Speciﬁcally distinguishes reports of daytime dozing behaviour from fatigue and drowsiness/sleepiness
○ Scores between 0 and 24
○ Higher scores indicate excessive sleepiness (11–12 mild; 13–16 moderate; >16 severe)
Functional and
performance status
6 min walk test (6MWT; baseline and W4)26
○ Recorded distance walked in metres and O2 saturation at rest and post-test
Physical activity monitoring (activPAL™ step count; baseline and W4)27
○ activPAL™ worn for 7 days at baseline prior to randomization and for 7 days prior to week 4
○ Discriminates between sedentary, upright, and stepping activities
○ Average daily step count documented
Montreal Cognitive Assessment (MoCA; baseline and W4. Shortened telephone-based MoCA administered at
D4 and D7)28
○ 30-item questionnaire assessing cognitive function
○ Scores between 0 and 30; ≥26 implies no cognitive impairment (telephone version scored 0 to 16)
○ Items that could be administered by phone assessed on Days 4 and 7
New York Heart Association class (NYHA; baseline, W4, and W12)29
○ Four classes based on symptoms (I, II, III, and IV)
○ Class IV denotes worst symptom status
Australia-modiﬁed Karnofsky Performance Status (AKPS; baseline, W4, and W12)30
○ Validated variant of Karnofsky Performance Status
○ Scored 0 to 100 in increments of 10 assigned to participants based on ability to perform activities of daily
living; higher scores imply better function
Quality of life Kansas City Cardiomyopathy Questionnaire-short form (KCCQ-12; baseline, W4, and W12)31
○ 12-item, self-administered instrument quantifying physical function, symptoms (frequency, severity, and
recent change), social function, self-efﬁcacy and knowledge, and quality of life
○ Combined single, overall summary score between 0 and 100
○ Higher scores indicate better functioning, fewer symptoms, and better disease-speciﬁc quality of life
Harmsa Opioid-relevant symptoms during each assessment using criteria established by the National Cancer Institute
(version 4.03) and graded accordingly (baseline, D2, D4, D7, W2, W3, W4, W8, and W12)32
○ Constipation
○ Confusion
○ Nausea
○ Vomiting
○ Memory impairment
○ Cognitive impairment
Karolinska Sleepiness Scale (KSS; baseline, D2, D4, D7, W2, W3, and W4)33
○ 9-point Likert scale of the patient’s level of drowsiness (1 = very alert to 9 = very sleepy)
Health economic
assessment
EuroQoL EQ-5D-5L (baseline, W4, W8, and W12)34
○ Self-administered, validated measure of health status
○ Five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression
○ Five levels [Level 1 = no problems, Level 2 = slight problems, Level 3 = moderate problems, Level 4 =
severe problems, Level 5 = unable (or extreme)] and a visual analogue self-rating scale
Health service use (baseline, W4, W8, and W12)
○ Participants recall speciﬁed service use over the past 4 weeks
Clinical assessments Standard examination (baseline and W4)
○ Resting pulse rate and blood pressure
○ Resting respiratory rate
○ Pulse oximetry
N-terminal proBNP (B-type natriuretic peptide) measurement (baseline and W4)
○ For sites with access to this test as part of clinical practice
Dose of ‘as required’ immediate release opioid for breathlessness (W4 and W12)
○ Patient diary: if, when, and the dose of any ‘as required’ dose of immediate release opioid solution taken
for breathlessness
aKnown opioid-related adverse events were measured at baseline and during follow-up.
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of whom 287 (74%) were ineligible, 53 (14%) declined, and
one (0.3%) was eligible but the trial closed prior to their ran-
domization. The most common reasons for ineligibility were
the absence of NYHA functional class III or IV (n = 59) and na-
triuretic peptide plasma concentrations below the inclusion
criteria (n = 34) (Figure 1).
The average age of randomized participants was 72 years
(range 39–89), and 84% were men (Table 2). All but one
had NYHA class III symptoms, and 78% had mMRC breathless-
ness grade 3 or 4. Baseline characteristics were generally well
balanced, but those assigned to placebo had more severe
breathlessness on the mMRC scale (Table 2).
For the primary endpoint, the raw mean (standard devia-
tion) scores were 5.3 (2.3) for those assigned to morphine
(n = 20) and 4.6 (2.4) for those assigned to placebo (n = 23)
(Table 3). The adjusted mean difference was 0.26 (95% conﬁ-
dence interval, 0.86 to 1.37, P = 0.65) in favour of the
placebo group (Figure 2). No adjusted mean difference of 1
point or more (clinically important difference) was observed
at 4 weeks between the groups for any NRS item.
From baseline to week 4, breathlessness measures, nota-
bly unpleasantness of, and distress due to, breathlessness im-
proved in both groups (Table 3). The improvement was
greater in those assigned to morphine compared with pla-
cebo in all but average intensity. All breathlessness scores in-
creased further during subsequent weeks in those assigned
to morphine but not in those assigned to placebo. Subjective
global impression of change ratings are presented in
Supporting Information, Table S1.
The median Australian-modiﬁed Karnofsky Performance
Status was 70 for both groups across all time points (Table
4; secondary outcomes). Neither group was excessively
sleepy or drowsy at baseline or week 4. There were no
between-group differences in the quality of life (Kansas) or
Figure 1 CONSORT ﬂow diagram of participant through the BreatheMOR-HF trial.
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cognition (Montreal) at any time point. At week 4, there was
a raw mean difference of 1113 steps per day favouring the
placebo group (activPAL™) but of 7.4 m in the walk test
favouring the morphine group. There was no exercise-related
desaturation and no change between baseline and week 4 in
either group. There was no change in vital signs at week 4.
The natriuretic peptide measures fell in both groups but
by more in the morphine group (Supporting Information,
Table S2).
Adherence is summarized in Supporting Information, Table
S3. All but one participant took at least one trial capsule. One
participant assigned to morphine withdrew the day after ran-
domization. Three participants withdrew fully from the trial
(i.e. from treatment and follow-up, Figure 1) and 16 partici-
pants [11 (52.4%) assigned to morphine and ﬁve (20.8%)
assigned to placebo] formally withdrew from treatment be-
fore the 12 week assessment [median time to treatment
withdrawal was 12 (range 4–56) days for morphine and 48
(range 7–57) days for placebo]. All continued to provide out-
come data. Participants were asked to take two capsules a
day for 84 days, which totalled to 168 tablets. Estimates of
the proportion of tablets taken ranged from 39–51% in those
assigned to morphine and 64–83% in those assigned to
placebo, depending on an assumption that none or all the
pills were taken if bottles were not returned.
There were 12 serious adverse events in the morphine
group and 15 in the placebo group (Supporting Information,
Table S4A). One death occurred in the placebo group. One
morphine group participant had a marked cognitive decline
from baseline at week 4 (25 to 14 MoCA points) that coin-
cided with a decline in renal function. The patient fully recov-
ered after stopping morphine. Non-serious adverse events
(Supporting Information, Table S4B) were more common in
those assigned to morphine (32 events) compared with pla-
cebo (22 events), although the excess was mainly due to
one individual assigned to morphine who had nine non-
serious events
After randomization, up to and including week 4, 18 (86%)
participants assigned to morphine and 13 (54%) to placebo
reported at least one harm of grade 1 or more, and 10
(48%) and 1 (4.2%), respectively, of grade 2 or more
(Supporting Information, Table S5A—up to week 4;
Supporting Information, Table S5B—weeks 8 and 12). Consti-
pation, nausea, and vomiting were more common in those
assigned to morphine rather than placebo throughout the
trial but were mainly mild (grade 1). Study laxative/placebo
Table 2 Baseline characteristics by randomized group, as randomized and as included in the primary outcome analysis
As randomized As analysed
Characteristica Morphine (n = 21) Placebo (n = 24) Morphine (n = 20) Placebo (n = 23)
Sex
Male 18 (85.7) 20 (83.3) 17 (85.0) 20 (87.0)
Female 3 (14.3) 4 (16.7) 3 (15.0) 3 (13.0)
Age, years 74.4 (6.0) 70.1 (14.0) 74.1 (6.0) 71.5 (12.6)
Ethnicity
White 21 (100.0) 24 (100.0) 21 (100.0) 24 (100.0)
NYHA class
III 20 (95.2) 24 (100.0) 19 (95.0) 23 (100.0)
IV 1 (4.8) 0 (0.0) 1 (5.0) 0 (0.0)
Resting pulse rate (per min) (radial) 77.0 (24.0) 77.0 (11.2) 76.8 (24.6) 77.1 (11.4)
Resting systolic blood pressure, mmHg 119.8 (24.2) 116.1 (14.5) 121.3 (23.8) 116.4 (14.8)
Resting diastolic blood pressure, mmHg 69.4 (12.3) 68.0 (11.6) 70.2 (12.1) 68.7 (11.2)
Resting respiratory rate (per min) 17.9 (6.8) 15.6 (4.4) 18.2 (6.8) 15.4 (4.4)
Pulse oximetry, % 97.1 (2.1) 96.7 (1.6) 97.1 (2.1) 96.7 (1.7)
mMRC gradeb
0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
2 7 (33.3) 3 (12.5) 7 (35.0) 3 (13.0)
3 11 (52.4) 21 (87.5) 10 (50.0) 21 (87.0)
4 3 (14.3) 0 (0.0) 3 (15.0) 0 (0.0)
eGFR, mL/min 53.0 (18.2) 62.2 (21.4) 53.9 (18.2) 61.8 (21.8)
NTproBNP, pg/mLc N = 20, 2963
(1883, 4743)
N = 22, 2587
(1436, 4636)
N = 19, 2843
(1860, 4230)
N = 21, 2646
(1761, 4636)
BNP, pg/mL N = 1, 528 () N = 2, 844 () N = 1, 528 () N = 2, 844 ()
Charlson Comorbidity
Index
6.7 (1.4) 6.2 (2.3) 6.7 (1.5) 6.4 (2.0)
aContinuous data are presented as mean (SD) and categorical data as n (%).
b0 = not troubled by breathlessness except on strenuous exercise; 1 = short of breath when hurrying or walking up a slight hill; 2 = walks
slower than contemporaries on the level because of breathlessness or has to stop for breath when walking at own pace; 3 = stops for
breath after about 100 m or after a few minutes on the level; 4 = too breathless to leave the house or breathless when dressing or
undressing.
cNTproBNP conducted by certain sites only; data are presented as median and interquartile range.
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was not taken by a substantial number of participants.
Treatment-emergent adverse events during the ﬁrst week
were three times more common in the morphine group and
were more common in participants with eGFR <54 mL/min
(the mean value) (Table 5), but all apart from one were grade
2 or less. Most presented by day 4 (see Supporting Informa-
tion, Figure S1). Harms by grade, treatment group, and time
point to week 4 are presented in Supporting Information,
Tables S5A and S5B.
Health service use and EQ-5D-5L measures at baseline and
follow-up are presented in Supporting Information, Tables
S6A and S6B.
Discussion
Main ﬁndings/results of the study
The BreatheMOR-HF trial is the ﬁrst to provide placebo-
controlled data for medium-duration, modiﬁed release,
steady state, low dose, oral morphine for people with persis-
tent breathlessness despite guideline-recommended treat-
ments for chronic heart failure. The trial failed to enrol the
planned number of participants but provides valuable insights
into the potential rate and severity of morphine-related
harm, particularly pertinent given the recent license
Table 3 Raw NRS summary scores for breathlessness by randomized group and time point, with adjusted mean difference between the
groups at primary time point of 4 weeks
NRS [0 (best) to 10 (worst)] N, Mean (SD) Time point
Morphine
(n = 21)
Placebo
(n = 24)
Total
(n = 45)
Adjusted mean difference
at W4 (95% CI), P value
How bad has your breathlessness
felt on average over the past 24 h?
Baseline 21, 5.8 (2.0) 24, 5.0 (1.9) 45, 5.3 (1.9) 0.26 (0.86 to 1.37), P = 0.65
D2 20, 4.7 (2.1) 24, 4.7 (1.6) 44, 4.7 (1.8)
D4 20, 4.4 (2.1) 24, 4.5 (1.7) 44, 4.5 (1.9)
D7 20, 4.6 (2.5) 24, 4.7 (1.7) 44, 4.6 (2.1)
W2 20, 4.8 (2.4) 24, 4.7 (2.0) 44, 4.8 (2.1)
W3 20, 4.7 (2.4) 23, 4.0 (2.2) 43, 4.3 (2.3)
W4 20, 5.3 (2.3) 23, 4.6 (2.4) 43, 4.9 (2.4)
W8 20, 4.9 (2.4) 23, 4.9 (2.1) 43, 4.9 (2.2)
W12 20, 4.6 (2.5) 22, 5.0 (2.2) 42, 4.8 (2.4)
How bad has your breathlessness felt
at its worst over the past 24 h?
Baseline 21, 7.2 (2.4) 24, 6.2 (1.9) 45, 6.7 (2.2) 0.15 (1.13 to 1.44), P = 0.82
D2 20, 5.2 (2.1) 24, 5.2 (2.2) 44, 5.2 (2.1)
D4 20, 4.5 (2.5) 24, 5.1 (2.5) 44, 4.8 (2.5)
D7 20, 5.2 (2.8) 24, 5.3 (2.3) 44, 5.3 (2.5)
W2 20, 5.3 (2.5) 24, 5.1 (2.0) 44, 5.2 (2.2)
W3 20, 5.0 (2.3) 23, 4.4 (2.5) 43, 4.7 (2.4)
W4 20, 5.9 (2.5) 23, 5.3 (2.6) 43, 5.6 (2.5)
W8 20, 6.0 (2.8) 23, 5.3 (2.5) 43, 5.6 (2.6)
W12 20, 5.1 (2.8) 22, 5.5 (2.0) 42, 5.3 (2.4)
How unpleasant has your breathlessness
been on average over the past 24 h?
Baseline 21, 5.6 (2.4) 24, 4.5 (2.0) 45, 5.0 (2.2) 0.15 (1.48 to 1.17), P = 0.82
D2 20, 4.3 (2.2) 24, 4.0 (1.8) 44, 4.1 (2.0)
D4 20, 4.0 (2.2) 24, 3.8 (2.1) 44, 3.9 (2.1)
D7 20, 4.4 (2.8) 24, 3.8 (2.1) 44, 4.1 (2.5)
W2 20, 4.3 (2.7) 24, 4.4 (2.2) 44, 4.4 (2.4)
W3 19, 3.8 (2.1) 23, 2.9 (2.2) 42, 3.3 (2.2)
W4 20, 4.7 (2.8) 23, 4.3 (2.1) 43, 4.4 (2.4)
W8 20, 4.3 (2.6) 23, 4.1 (2.5) 43, 4.2 (2.6)
W12 20, 4.3 (3.0) 22, 4.3 (2.6) 42, 4.3 (2.7)
How much distress has your breathlessness
caused you on average over the past 24 h?
Baseline 21, 5.7 (2.4) 24, 4.1 (2.3) 45, 4.8 (2.5) 0.55 (1.99 to 0.88), P = 0.45
D2 20, 3.3 (2.5) 24, 3.3 (2.1) 44, 3.3 (2.2)
D4 20, 2.7 (2.5) 24, 3.1 (2.7) 44, 2.9 (2.6)
D7 20, 3.5 (3.0) 24, 3.3 (2.3) 44, 3.4 (2.6)
W2 20, 3.8 (3.2) 24, 3.1 (2.6) 44, 3.4 (2.9)
W3 20, 3.3 (2.7) 22, 2.8 (2.4) 42, 3.0 (2.5)
W4 20, 4.2 (3.3) 23, 3.8 (2.6) 43, 4.0 (2.9)
W8 20, 4.2 (3.1) 23, 3.6 (2.6) 43, 3.8 (2.8)
W12 20, 3.8 (2.9) 22, 4.0 (2.4) 42, 3.9 (2.6)
How much pain have you had on average
over the past 24 h?
Baseline 21, 1.9 (3.1) 24, 1.2 (2.1) 45, 1.5 (2.6) 0.05 (1.29 to 1.20), P = 0.94
D2 20, 1.3 (2.4) 24, 1.3 (2.0) 44, 1.3 (2.1)
D4 20, 1.3 (2.5) 24, 0.9 (1.7) 44, 1.0 (2.1)
D7 18, 0.8 (1.9) 24, 0.7 (1.6) 42, 0.8 (1.7)
W2 20, 1.3 (2.5) 24, 0.8 (1.4) 44, 1.0 (2.0)
W3 20, 0.9 (1.9) 23, 1.0 (1.6) 43, 0.9 (1.7)
W4 20, 1.5 (2.8) 23, 1.1 (1.9) 43, 1.3 (2.3)
W8 19, 1.9 (3.4) 23, 1.8 (3.0) 42, 1.8 (3.1)
W12 20, 2.0 (3.3) 22, 0.9 (2.0) 42, 1.4 (2.8)
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extension to chronic breathlessness (including that due to
heart failure) for a sustained release oral morphine prepara-
tion (Kapanol™) by the Therapeutic Goods Administration in
Australia. Constipation, nausea, and vomiting, albeit mainly
mild, were more common in the morphine group, as was
study drug withdrawal. This highlights the need for early skil-
ful management of morphine-related side effects and careful
clinical decision making regarding prescription of morphine
for chronic breathlessness given the persisting lack of robust
evidence of beneﬁt in this patient population.
Strengths and limitations
The major limitation of the study is its early termination and
consequent lack of power; data can only be interpreted as
preliminary. Recruitment challenges are related to (i) some
eligibility criteria, particularly the natriuretic peptide thresh-
old, (ii) the Research Ethics Committee requirement that par-
ticipants avoided driving for the ﬁrst week (despite no
evidence base37), and (iii) delays in opening recruitment sites.
Suboptimal adherence to, and withdrawal from, study drug
weakened our ﬁndings. Numbers are too small for a per pro-
tocol analysis, but inclusion of data from those who stopped
study drug may have diluted beneﬁt experienced by those
who tolerated morphine.
The major strength is the double-blind, placebo-controlled
design and trial duration. Data quality and completion rates
(apart from physical activity and exercise tolerance) were very
high, with minimal full study withdrawal. In addition, our study
recruited the targeted population with advanced disease.
What this study adds
Although participants had advanced disease, there were no
excess serious adverse events in the morphine group. We
found no respiratory depression consistent with a recent sys-
tematic review and meta-analysis.17,18
The reports of (mainly mild) constipation, nausea, and
vomiting in the morphine group are similar to other pub-
lished reports of low dose morphine for breathless-
ness14,15,38,39 but are nonetheless important. In this study
protocol, anti-emetics were not co-prescribed from study
drug initiation in the same way as laxatives but given in re-
sponse to emergent nausea. It is possible that patients with
heart failure and renal dysfunction may be susceptible to
nausea as blood brain barrier permeability is increased, at
least in acute kidney injury,40 and initial co-prescription might
be useful. Recommendations for management of morphine-
related side effects are available but may be unfamiliar to
non-palliative care or non-pain specialists.41
Impaired cognition is cited as a particular fear of morphine
treatment by both patients and clinicians,42 but we found no
excess sleepiness or cognitive impairment in the morphine
group apart from one patient with deterioration in renal
function. We saw a reduction in daily steps with morphine
but no increase in daytime sleepiness. The walk distance
Figure 2 Mean average breathlessness by randomized group and time point as measured on a numerical rating scale from 0 (no breathlessness) to 10
(worst imaginable breathlessness) adjusted for baseline NRS.
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Table 4 Other secondary outcome scores by randomized group and time point
Outcome
Morphine
(n = 21)
Placebo
(n = 24)
Total
(n = 45)
Adjusted mean difference
at W4 (95% CI), P value
Australian-modiﬁed Karnofsky Performance Status [10 (comatose) to 100 (normal)]
Baseline 21 70 (60, 80) 24 70 (60, 70) 45 70 (60, 70) 2.1 (7.0 to 2.8),
P = 0.40Week 4 20 70 (60, 75) 22 70 (70, 70) 42 70 (70, 70)
Week 12 22 70 (60, 80) 20 70 (60, 80) 42 70 (60, 80)
Cardiomyopathy Questionnaire (Kansas City) [1 (extremely limited) to 100 (not limited)]
Baseline 21 36.6 (14.7) 24 40.2 (11.9) 45 38.5 (13.2) 2.7 (9.7 to 4.3),
P = 0.44Week 4 20 37.2 (16.0) 22 44.1 (12.9) 42 40.8 (14.7)
Week 12 20 42.2 (22.0) 22 42.3 (17.7) 42 42.2 (19.6)
Epworth Sleepiness Scale (0–24; higher score = greater sleepiness)
Baseline 21 9.6 (4.1) 24 9.5 (4.8) 45 9.6 (4.5) 1.3 (0.8 to 3.5),
P = 0.23Week 4 20 10.6 (5.2) 22 9.4 (4.3) 42 10.0 (4.8)
Karolinska Sleepiness Scale (1 = very alert to 9 = very sleepy)
Baseline 21 3.0 (1.5) 24 3.3 (1.6) 45 3.2 (1.5) 0.3 (0.5 to 1.2),
P = 0.45Day 2 20 3.8 (1.7) 24 3.4 (1.2) 44 3.6 (1.4)
Day 4 20 3.8 (1.9) 24 3.8 (1.9) 44 3.8 (1.8)
Day 7 20 4.6 (2.5) 24 3.5 (1.7) 44 4.0 (2.2)
Week 2 20 3.2 (1.4) 24 3.5 (1.9) 44 3.4 (1.7)
Week 3 20 3.1 (1.4) 23 3.2 (1.8) 43 3.1 (1.6)
Week 4 20 3.3 (1.5) 23 3.0 (1.6) 43 3.2 (1.5)
Montreal Cognitive Assessment [0–30 (0–16 phone version); lower scores = greater cognitive impairment]
Baseline 21 25.1 (1.9) 24 25.4 (3.1) 45 25.2 (2.6) 0.5 (2.2 to 1.1),
P = 0.53Day 4 (phone version) 19 14.1 (1.3) 21 14.3 (1.9) 40 14.2 (1.6)
Day 7 (phone version) 18 14.2 (1.1) 23 14.7 (1.3) 41 14.5 (1.2)
Week 4 20 26.2 (3.3) 21 26.8 (2.3) 41 26.5 (2.8)
6 min walk test [distance walked (m)]
Baseline 18 153 (105, 273) 24 179 (133, 255) 42 160 (120, 270) 18.7 (48.8 to 86.3),
P = 0.59Week 4 13 169 (120, 250) 17 165 (90, 270) 30 167 (104, 270)
O2 saturation at rest (%)
Baseline 18 97 (96, 99) 24 97 (95, 98) 42 97 (96, 98) 0.7 (1.8 to 0.4),
P = 0.23Week 4 13 96 (95, 98) 16 97 (96, 98) 29 97 (95, 98)
O2 saturation at end (%)
Baseline 18 98 (97, 98) 24 97 (96, 99) 42 98 (97, 99) 0.2 (1.3 to 0.9),
P = 0.74Week 4 13 97 (96, 98) 16 97 (96, 99) 29 97 (96, 98)
activPAL™ (average steps per day)
Baseline 20 2503 (976, 3700) 22 2207 (473, 3183) 42 2315 (589, 3445) 728.2 (1438.5 to 17.8),
P = 0.05Week 4 19 1943 (361, 2975) 17 2717 (1744, 3143) 36 2259 (1061, 3063)
Data are N, mean (SD) or N, median (IQR).
Table 5 Number of participants experiencing a treatment-emergent harm within the ﬁrst week of follow-up, stratiﬁed by median base-
line eGFR of 54 mL/min
Grade ≤ 2 Grade ≥ 3
Morphine Placebo Morphine Placebo
eGFR ≤ 54
(n = 14)
eGFR > 54
(n = 7)
eGFR ≤ 54
(n = 9)
eGFR > 54
(n = 15)
eGFR ≤ 54
(n = 14)
eGFR > 54
(n = 7)
eGFR ≤ 54
(n = 9)
eGFR > 54
(n = 15)
Confusion 0 (0.0) 1 (14.3) 0 (0.0) 1 (6.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Constipation 9 (64.3) 5 (71.4) 0 (0.0) 2 (13.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Vomiting 5 (35.7) 1 (14.3) 1 (11.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Nausea 9 (64.3) 3 (42.9) 1 (11.1) 2 (13.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Memory impairment 1 (7.1) 1 (14.3) 0 (0.0) 1 (6.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Cognitive disturbance 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (7.1) 0 (0.0) 0 (0.0) 0 (0.0)
At least one 11 (78.6) 6 (85.7) 1 (11.1) 5 (33.3) 1 (7.1) 0 (0.0) 0 (0.0) 0 (0.0)
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increased further in the morphine group, but there was a
high proportion of missing data making interpretation difﬁ-
cult. The lack of desaturation on exertion is reassuring and
consistent with previous ﬁndings.17
In the morphine group, all breathlessness measures, apart
from week 4 average breathlessness, had greater improve-
ment from baseline than the placebo group. Improvements
in all breathlessness measures were sustained or improved
further by weeks 8 and 12 in the morphine group and
reached clinically important differences. Further improve-
ment beyond week 4 was not seen in the placebo group in
any breathlessness measure, and none reached clinical signif-
icance. At baseline, the breathlessness scores were on aver-
age worse in the morphine group than control by around a
clinically important difference (1 point) for each measure
and so may represent a group more likely to respond to mor-
phine.43 However, such ﬁndings can only be interpreted as a
preliminary signal of beneﬁt.
Implications for clinical practice and research
Morphine should only be prescribed in people with heart fail-
ure when other measures have not helped and only with
early recourse to management of potential side effects. Fears
of serious harm are unsubstantiated.
The observed pattern of improvement in breathlessness
measures in the morphine group suggests that an adequately
sized trial would be useful. Lessons learned from recruitment
and attrition challenges should be incorporated in a new
study. A dose titration step should be included, and an initia-
tion side-effect management plan should be put in place. The
eligibility criterion relating to natriuretic peptide should be re-
moved but included as a secondary outcome in view of the
observation that levels reduced by more in the morphine
group, a ﬁnding seen in previous work and the signiﬁcance
of which is unknown.14 The extensive trials unit support re-
quired to navigate the complex governance required to open
multiple recruitment sites needs to be planned for.
The observed standard deviation of the primary outcome
measure was lower than the anticipated 2.55 in each group
at all time points; the correlation between the baseline and
week 4 measures of the primary endpoint was 0.67. A
recalculated sample size of 150 patients would provide 80%
power to detect the same planned difference, assuming a
standard deviation of 2.55, 5% signiﬁcance level, a conserva-
tive correlation of 0.65 between the baseline and week 4
measures, and 20% attrition.
Conclusions
We were unable to answer our primary objectives due to in-
adequate power. However, we provide novel preliminary
placebo-controlled data relating to the beneﬁt and safety of
medium-term oral modiﬁed release morphine that will help
inform clinical practice and the design of a future trial.
Acknowledgements
The authors would like to thank the participants for taking
part in the trial; the Principal Investigators (PI) and research
nurses at each site for recruiting participants and completing
the trial documentation; Prof. G. Richardson for health eco-
nomic advice; members of the trial steering committee Dr J.
McMurray (independent Chair), Dr M. Bennett, Dr J. War-
wick, Dr O. Agbaje, and Doreen Edgar (Patient Public Involve-
ment representative) and members of the data monitoring
and ethics committee Dr M. Fallon (independent Chair) Dr
A. Crook and Dr R Gardner for their advice, overseeing the
study and reviewing adverse event data. The BreatheMOR-
HF PIs include Dr C. Boos, Dr A. Clark, Dr J. Cooke, Dr M.
Denvir, Dr Gale, Dr B. Gordon, Dr K. Hogg, Dr S. Jenkins, Dr
J. Murphy, Dr S. Oxberry, Dr P. Sheridan, Dr H. Thomas, and
Dr A. Thorns. The BreatheMOR-HF research team acknowl-
edges the support of the National Institute of Health Re-
search Clinical Research Network (NIHR CRN).
Conﬂict of interest
D.C.C. has received an unrestricted research grant from
Mundipharma, is an unpaid member of an advisory board
for Helsinn Pharmaceuticals, and has consulted Mayne
Pharma and received intellectual property payments from
them. M.J.J. has received consulting payments from Mayne
Pharma. No authors have any conﬂicting interests with the
content of this manuscript.
Author contributions
M.J., D.C.C., and A.L.C. did the concept and design. Protocol
authors were M.J.J., D.C.C., J.C., A.L.C., R.G., K.H., J.M., S.O.,
G.R., D.T., V.A., and S.C. Trial conduct and data management
were performed by S.C., K.B., L.J., and K.H. Data collection
was carried out by K.H., S.O., J.G., M.J.J., and A.L.C. C.F., R.
G., and V.A. analysed the data. All authors did the data inter-
pretation, revised the manuscript for intellectual content,
and approved the ﬁnal version.
Funding
This work was supported by the British Heart Foundation
(grant number CS/13/2/30584).
10 M.J. Johnson et al.
ESC Heart Failure (2019)
DOI: 10.1002/ehf2.12498
Data management and sharing
Requests to access BreatheMOR-HF data can be made to the
corresponding author. Requests will be considered on a case-
by-case basis and managed according to the York Trials Unit,
University of York processes and procedures. The full proto-
col can be accessed through the corresponding author.
Supporting information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Global Impression of Change relating to breathless-
ness, at week 4 (valid data provided by 41 participants).
Table S2. Clinical assessments and NYHA class at week 4 by
randomised group.
Table S3. Study drug use by randomised group
Table S4. (A) Serious adverse events. (B) Non-serious adverse
events.
Table S5. (A) Harms by grade, treatment group and time
point, up to week 4. (B) Harms by grade, treatment group
and time point, weeks 8 and 12.
Table S6. (A) EQ-5D-5L, and health service use during previ-
ous 4 weeks, at baseline and week 4 by randomised group.
(B) EQ-5D-5L, and health service use during previous 4 weeks,
at weeks 8 and 12 by randomised group.
Figure S1. Supporting information
References
1. Nordgren L, Sorensen S. Symptoms
experienced in the last six months of
life in patients with end-stage heart
failure. Eur J Cardiovasc Nurs 2003; 2:
213–217.
2. Currow DC, Dal GE, Ferreira D, Johnson
MJ, McCaffrey N, Ekstrom M. Chronic
breathlessness associated with poorer
physical and mental health-related qual-
ity of life (SF-12) across all adult age
groups. Thorax 2017; 72: 1151–1153.
3. Smith AK, Currow DC, Abernethy AP,
Johnson MJ, Miao Y, Boscardin WJ,
Ritchie CS. Prevalence and outcomes of
breathlessness in older adults: a na-
tional population study. J Am Geriatr
Soc 2016; 64: 2035–2041.
4. Hutchinson A, Pickering A, Williams P,
Bland JM, Johnson MJ. Breathlessness
and presentation to the emergency de-
partment: a survey and clinical record
review. BMC Pulm Med 2017; 17: 53.
5. Parshall MB. Adult emergency visits for
chronic cardiorespiratory disease: does
dyspnea matter? Nurs Res 1999; 48:
62–70.
6. Farquhar MC, Prevost A, McCrone P,
Brafman-Price B, Bentley A, Higginson
IJ, Todd C, Booth S. Is a specialist
breathlessness service more effective
and cost-effective for patients with ad-
vanced cancer and their carers than
standard care? Findings of a mixed-
method randomised controlled trial.
BMC Med 2014; 12: 194.
7. Ekstrom M, Bajwah S, Bland JM, Currow
DC, Hussain JA, Johnson MJ. One evi-
dence base; three stories: do opioids re-
lieve chronic breathlessness? Thorax
2018; 73: 88–90.
8. Higginson IJ, Bausewein C, Reilly CC,
Gao W, Gysels M, Dzingina M, McCrone
P, Booth S, Jolley CJ, Moxham J. An in-
tegrated palliative and respiratory care
service for patients with advanced dis-
ease and refractory breathlessness: a
randomised controlled trial. Lancet
Respir Med 2014; 2: 979–987.
9. von Leupoldt A, Sommer T, Kegat S,
Baumann HJ, Klose H, Dahme B, Büchel
C. Dyspnea and pain share emotion-
related brain network. Neuroimage
2009; 48: 200–206.
10. Baumgartner U, Buchholz HG,
Bellosevich A, Magerl W, Siessmeier T,
Rolke R, Höhnemann S, Piel M, Rösch
F, Wester HJ, Henriksen G. High opiate
receptor binding potential in the human
lateral pain system. Neuroimage 2006;
30: 692–699.
11. Gifford AH, Mahler DA, Waterman LA,
Ward J, Kraemer WJ, Kupchak BR, Baird
JC. Neuromodulatory effect of endoge-
nous opioids on the intensity and un-
pleasantness of breathlessness during
resistive load breathing in COPD. COPD
2011; 8: 160–166.
12. Mahler DA, Murray JA, Waterman LA,
Ward J, Kraemer WJ, Zhang X, Baird
JC. Endogenous opioids modify dys-
pnoea during treadmill exercise in pa-
tients with COPD. Eur Respir J 2009;
33: 771–777.
13. Barnes H, McDonald J, Smallwood N,
Manser R. Opioids for the palliation of
refractory breathlessness in adults with
advanced disease and terminal illness.
Cochrane Database Syst Rev 2016; 3:
CD011008.
14. Johnson MJ, McDonagh TA, Harkness A,
McKay SE, Dargie HJ. Morphine for the
relief of breathlessness in patients with
chronic heart failure-a pilot study. Eur J
Heart Fail 2002; 4: 753–756.
15. Oxberry SG, Torgerson DJ, Bland JM,
Clark AL, Cleland JG, Johnson MJ.
Short-term opioids for breathlessness in
stable chronic heart failure: a random-
ized controlled trial. Eur J Heart Fail
2011; 13: 1006–1012.
16. Oxberry SG, Bland JM, Clark AL,
Cleland JG, Johnson MJ. Repeat dose
opioids may be effective for breathless-
ness in chronic heart failure if given for
long enough. J Palliat Med 2013; 16:
250–255.
17. Verberkt CA, van den Beuken-van
Everdingen MHJ, Schols JMGA, Datla
S, Dirksen CD, Johnson MJ, van Kuijk
SM, Wouters EF, Janssen DJ. Respiratory
adverse effects of opioids for breathless-
ness: a systematic review and meta-
analysis. Eur Respir J 2017; 50: 1701153.
18. Rocker GM, Young J, Horton R. Using
opioids to treat dyspnea in advanced
COPD: a survey of Canadian clinicians.
Chest (accessible at chestnet.org).
2008. Ref Type: Abstract
19. Cockcroft DW, Gault MH. Prediction of
creatinine clearance from serum creati-
nine. Nephron 1976; 16: 31–41.
20. Charlson M, Szatrowski TP, Peterson J,
Gold J. Validation of a combined comor-
bidity index. J Clin Epidemiol 1994; 47:
1245–1251.
21. Stenton C. The MRC breathlessness
scale. Occup Med (Lond) 2008; 58:
226–227.
22. Gift AG, Narsavage G. Validity of the nu-
meric rating scale as a measure of dys-
pnea. Am J Crit Care 1998; 7: 200–204.
23. Jaeschke R, Singer J, Guyatt GH. Mea-
surement of health status. Ascertaining
the minimal clinically important differ-
ence. Control Clin Trials 1989; 10:
407–415.
Oral modiﬁed release morphine for breathlessness in chronic heart failure 11
ESC Heart Failure (2019)
DOI: 10.1002/ehf2.12498
24. Breivik H, Borchgrevink PC, Allen SM,
Rosseland LA, Romundstad L, Hals EK,
Kvarstein G, Stubhaug A. Assessment of
pain. Br J Anaesth 2008; 101: 17–24.
25. Johns MW. A new method for measur-
ing daytime sleepiness: the Epworth
sleepiness scale. Sleep 1991; 14:
540–545.
26. Ingle L, Shelton RJ, Rigby AS, Nabb S,
Clark AL, Cleland JG. The reproducibil-
ity and sensitivity of the 6-min walk test
in elderly patients with chronic heart
failure. Eur Heart J 2005; 26:
1742–1751.
27. Grant PM, Ryan CG, Tigbe WW, Granat
MH. The validation of a novel activity
monitor in the measurement of posture
and motion during everyday activities.
Br J Sports Med 2006; 40: 992–997.
28. Gallagher R, Sullivan A, Burke R, Hales
S, Gillies G, Cameron J, Saliba B, Toﬂer
G. Mild cognitive impairment, screen-
ing, and patient perceptions in heart
failure patients. J Card Fail 2013; 19:
641–646.
29. The Criteria Committee of the New York
Heart Association. Nomenclature and
criteria for diagnosis of diseases of the
heart and great vessels. 6th ed. Boston,
Mass: Little, Brown & Co; 1994.
30. Abernethy AP, Shelby-James T, Fazekas
BS, Woods D, Currow DC. The
Australia-modiﬁed Karnofsky Perfor-
mance Status (AKPS) scale: a revised
scale for contemporary palliative care
clinical practice [ISRCTN81117481].
BMC Palliat Care 2005; 4: 7.
31. Jones P, Gosch K, Yi L, Reid K, Tang F,
Chan P, Spertus J. The KCCQ-12: A short
version of the Kansas City Cardiomyopa-
thy Questionnaire. Circ Cardiovasc Qual
Outcomes 2013; 6: A248.
32. National Institute for Health, National
Cancer Institute. Common terminology
criteria for adverse events version 4.03.
1-6-2010. US Department of Health
and Human Services. 21-7-2018. Ref
Type: Report
33. Kaida K, Takahashi M, Akerstedt T,
Nakata A, Otsuka Y, Haratani T,
Fukasawa K. Validation of the
Karolinska sleepiness scale against per-
formance and EEG variables. Clin
Neurophysiol 2006; 117: 1574–1581.
34. Kind P. The EuroQoL instrument: an in-
dex of health-related quality of life. In
Spilker B., ed. Quality of life and
pharmacoeconomics in clinical trials.
Philadelphia: Lippincott-Raven; 1996.
35. Akaike H. A new look at the statistical
model identiﬁcation. IEEE Trans Autom
Control 1974; 19: 716–723.
36. Rennie D. CONSORT revised—improv-
ing the reporting of randomized trials.
JAMA 2001; 285: 2006–2007.
37. Ferreira DH, Boland JW, Phillips JL, Lam
L, Currow DC. The impact of therapeutic
opioid agonists on driving-related psy-
chomotor skills assessed by a driving
simulator or an on-road driving task: a
systematic review. Palliat Med 2018; 32:
786–803.
38. Abernethy AP, Currow DC, Frith P,
Fazekas BS, McHugh A, Bui C.
Randomised, double blind, placebo con-
trolled crossover trial of sustained re-
lease morphine for the management of
refractory dyspnoea. BMJ 2003; 327:
523–528.
39. Currow DC, McDonald C, Oaten S,
Kenny B, Allcroft P, Frith P, Briffa M,
Johnson MJ, Abernethy AP. Once-daily
opioids for chronic dyspnea: a dose in-
crement and pharmacovigilance study.
J Pain Symptom Manage 2011; 42:
388–399.
40. Nongnuch A, Panorchan K, Davenport
A. Brain-kidney crosstalk. Crit Care
2014; 18: 225.
41. Cherny N, Ripamonti C, Pereira J, Davis
C, Fallon M, McQuay H, Mercadante S,
Pasternak G, Ventafridda V, for the Ex-
pert Working Group of the European As-
sociation of Palliative Care Network.
Strategies to manage the adverse effects
of oral morphine: an evidence-based re-
port. J Clin Oncol 2001; 19: 2542–2554.
42. Jacobsen R, Liubarskiene Z, Moldrup C,
Christrup L, Sjogren P, Samsanaviciene
J. Barriers to cancer pain management:
a review of empirical research. Medicina
(Kaunas) 2009; 45: 427–433.
43. Johnson MJ, Bland JM, Oxberry SG,
Abernethy AP, Currow DC. Opioids for
chronic refractory breathlessness: pa-
tient predictors of beneﬁcial response.
Eur Respir J 2013; 42: 758–766.
12 M.J. Johnson et al.
ESC Heart Failure (2019)
DOI: 10.1002/ehf2.12498
